search
Back to results

A Randomized Controlled Trial of LOT-CRT Versus conventionaL BiVP in Heart Failure Patients With NICD (BATTLE)

Primary Purpose

Heart Failure, Intraventricular Block

Status
Not yet recruiting
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
LOT-CRT group
BiVP group
Sponsored by
The First Affiliated Hospital with Nanjing Medical University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Heart Failure focused on measuring Left bundle branch area pacing

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Ischemic or non ischemic cardiomyopathy Optimal medical therapy for at lest 3 months NYHA class II-IV LVEF≤35% as assessed by echocardiography Sinus rhythm (may have paroxysmal atrial fibrillation) QRS duration ≥ 150ms Intraventricular block (NICD), QRS morphology is neither LBBB nor RBBB Exclusion Criteria: Valvular heart disease that requires or has undergone surgical intervention After mechanical tricuspid valve replacement Persistent or permanent atrial fibrillation or atrial flutter Second or third degree atrioventricular block Have a history of acute myocardial infarction within 3 months prior to enrollment Patient's expected survival time is less than 12 months Pregnant or planned to conceive Ventricular septal hypertrophy (ventricular septal thickness exceeds 15mm at the end of diastole) Patients with simple and persistent left superior vena cava Patients with existing pacemaker implantation

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    LOT-CRT group

    BiVP group

    Arm Description

    In this arm, an right artrial (RA) lead, an implantable cardioverter defibrillator (ICD) lead and a LV pacing lead are placed are conventionally implanted. A left bundle branch pacing(LBBP) lead is attempted to be placed.

    In this arm, an RA lead , an ICD lead and a LV pacing lead are placed.

    Outcomes

    Primary Outcome Measures

    Left ventricular ejection fraction(LVEF)
    Changes from baseline LVEF(unit: %) assessed by echocardiography at follow-up

    Secondary Outcome Measures

    Paced QRS duration
    Paced QRS duration is evaluated postoperative day 1 and 1 months, 3 months and 6 months after implantation.
    A combined clinical endpoint of all-cause mortality and heart failure hospitalization,
    Including date and number of all-cause mortalityand heart failure hospitalization,
    Left ventricular end systolic volume(LVESV)
    Changes from baseline LVESV(unit: mL) assessed by echocardiography at follow-up
    Left ventricular end diastolic volume(LVEDV)
    Changes from baseline LVEDV(unit: mL) assessed by echocardiography at follow-up
    Left ventricular end systolic diameter(LVESD)
    Changes from baseline LVESD(unit: mm) assessed by echocardiography at follow-up
    Left ventricular end diastolic diameter(LVEDD)
    Changes from baseline LVEDD(unit: mm) assessed by echocardiography at follow-up
    Change in Quality Of Life Questionnaire score between baseline and follow-up
    Reflect the effect of cardiac funtion on quality of life, and higher scores represent a worse outcome
    Changes in New York Heart Association Heart Function Classification between baseline and follow-up
    The higher the classification, the more severe the heart failure symptoms(four levels: I, II, III and IV)
    Changes in 6-minute Walk Distance between baseline and follow-up
    Distance that a participant walk within 6 minutes
    Changes in concentration of NT-proBNP in blood between baseline and follow-up
    Blood test is performed at each time frame to determine the concentration of NT-proBNP(unit: pg/mL)
    Incidence of stroke events
    Including date and number of stroke
    A combined arrhythmia endpoint of new-onset atrial fibrillation and malignant ventricular arrhythmia
    Including date and number of new-onset atrial fibrillation and malignant ventricular arrhythmia
    Success rate of LBBAP implantation Success rate of LBBAP implantation Success rate of LBBAP implantation Success rate of LBBAP implantation Success rate of LBBAP implantation
    Success rate of LBBAP in LOT-CRT group

    Full Information

    First Posted
    September 25, 2023
    Last Updated
    September 25, 2023
    Sponsor
    The First Affiliated Hospital with Nanjing Medical University
    Collaborators
    Shanghai Zhongshan Hospital, Sir Run Run Shaw Hospital, Fu Wai Hospital, Beijing, China, West China Hospital, The First Affiliated Hospital of Dalian Medical University, The First People's Hospital of Yunnan, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Guangdong Provincial People's Hospital, Shanghai Tong Ren Hospital, Fujian Provincial Hospital, Fujian Medical University Union Hospital
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT06061627
    Brief Title
    A Randomized Controlled Trial of LOT-CRT Versus conventionaL BiVP in Heart Failure Patients With NICD
    Acronym
    BATTLE
    Official Title
    A Randomized Controlled Trial of Left Bundle brAnch opTimized Cardiac Resynchronization Therapy Versus conventionaL Bi-vEntricular Pacing in Heart Failure Patients With Nonspecific Intraventricular Conduction Delay
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    September 2023 (Anticipated)
    Primary Completion Date
    March 2027 (Anticipated)
    Study Completion Date
    March 2027 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    The First Affiliated Hospital with Nanjing Medical University
    Collaborators
    Shanghai Zhongshan Hospital, Sir Run Run Shaw Hospital, Fu Wai Hospital, Beijing, China, West China Hospital, The First Affiliated Hospital of Dalian Medical University, The First People's Hospital of Yunnan, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Guangdong Provincial People's Hospital, Shanghai Tong Ren Hospital, Fujian Provincial Hospital, Fujian Medical University Union Hospital

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    BATTLE study has been designed as a prospective, multi-center, randomized, controlled trial. This study will enroll 83 patients with chronic heart failure accompanied by intraventricular block (NICD) over an estimated recruitment period of 3 years. An LOT-CRT group will be compared with a group of conventional BiVP in the follow-up of at least 6 months. The study aimed to compare the curative effect of LOT-CRT in preserving LV systolic function with traditional BiVP in chronic heart failure patients with NICD.
    Detailed Description
    Cardiac resynchronization therapy is a standardized treatment strategy for patients with chronic heart failure complicated by wide QRS waves. With the continuous development of physiological pacing technology, traditional cardiac resynchronization therapy, namely biventricular pacing technology, is constantly challenged. Left bundle branch area pacing (LBBAP), as the main method of physiological pacing technology, is currently increasingly widely used in clinical practice. In recent years, research has mainly focused on heart failure patients with wide QRS waves such as non ischemic cardiomyopathy and typical left bundle branch block (LBBB). The recently published LBBP-RESYNC study was a randomized controlled study comparing left bundle branch pacing (LBBP) and biventricular pacing. The results showed that LBBP can achieve better improvement in left ventricular function compared to traditional biventricular pacing. Compared with patients with typical LBBB, traditional biventricular pacing synchronized treatment is less effective in chronic heart failure patients accompanied by intraventricular block (NICD), which is closely related to the electrophysiological mechanism of LBBB. The blocking site of typical LBBB is generally located within the His bundle to the proximal end of the left bundle branch, while the distal end of the left bundle branch is relatively healthy. Therefore, LBBP can completely correct this type of LBBB and significantly narrow the QRS wave; The electrophysiological mechanism of NICD is relatively complex, and there may be multiple blocking sites, and LBBP cannot be completely corrected. How to improve the treatment efficacy and clinical prognosis of chronic heart failure patients with NICD is an important scientific issue that urgently needs to be solved. It is unclear whether left bundle branch pacing technology can provide support for cardiac function in such patients. Traditional biventricular pacing combines right ventricular and left epicardial pacing; LBBAP combined with left ventricular epicardial pacing, also known as LOT-CRT, is an innovative pacing method. This study aims to explore the application value of LBBAP in patients with chronic heart failure and NICD.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Heart Failure, Intraventricular Block
    Keywords
    Left bundle branch area pacing

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    Care ProviderOutcomes Assessor
    Allocation
    Randomized
    Enrollment
    86 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    LOT-CRT group
    Arm Type
    Experimental
    Arm Description
    In this arm, an right artrial (RA) lead, an implantable cardioverter defibrillator (ICD) lead and a LV pacing lead are placed are conventionally implanted. A left bundle branch pacing(LBBP) lead is attempted to be placed.
    Arm Title
    BiVP group
    Arm Type
    Active Comparator
    Arm Description
    In this arm, an RA lead , an ICD lead and a LV pacing lead are placed.
    Intervention Type
    Procedure
    Intervention Name(s)
    LOT-CRT group
    Intervention Description
    In addition to the leads implanted in BiVP group, it is also necessary to implant the left bundle branch area pacing(LBBAP) leads LBBAP includes LBBP and LVSP. LBBP is defined if fulfilling criterion 1 and at least one in criteria 2: Paced morphology of RBBD in surface lead V1 (QR, Qr, rSr', rSR' or Qrs); One of the following should be met, while the pacing threshold ≤ 1.5V/0.5ms: Selective LBBP capture pattern appears, with an iso-electrical window between the pacing spike and QRS onset; When reducing the output voltage, the LVAT undergoes a sudden change of>10ms; If criterion 1 is fulfilled but none in criteria 2 is met, the procedure is considered to be left ventricular septal pacing (LVSP).
    Intervention Type
    Procedure
    Intervention Name(s)
    BiVP group
    Intervention Description
    Implantation of a LV pacing lead is attempted using the standard-of-care technique first.
    Primary Outcome Measure Information:
    Title
    Left ventricular ejection fraction(LVEF)
    Description
    Changes from baseline LVEF(unit: %) assessed by echocardiography at follow-up
    Time Frame
    Baseline; 6-month follow-up
    Secondary Outcome Measure Information:
    Title
    Paced QRS duration
    Description
    Paced QRS duration is evaluated postoperative day 1 and 1 months, 3 months and 6 months after implantation.
    Time Frame
    Postoperative day 1; 1-month,3-month and 6-month follow-up
    Title
    A combined clinical endpoint of all-cause mortality and heart failure hospitalization,
    Description
    Including date and number of all-cause mortalityand heart failure hospitalization,
    Time Frame
    6-month follow-up
    Title
    Left ventricular end systolic volume(LVESV)
    Description
    Changes from baseline LVESV(unit: mL) assessed by echocardiography at follow-up
    Time Frame
    Baseline; 3-month, 6-month follow-up
    Title
    Left ventricular end diastolic volume(LVEDV)
    Description
    Changes from baseline LVEDV(unit: mL) assessed by echocardiography at follow-up
    Time Frame
    Baseline; 3-month, 6-month follow-up
    Title
    Left ventricular end systolic diameter(LVESD)
    Description
    Changes from baseline LVESD(unit: mm) assessed by echocardiography at follow-up
    Time Frame
    Baseline; 3-month, 6-month follow-up
    Title
    Left ventricular end diastolic diameter(LVEDD)
    Description
    Changes from baseline LVEDD(unit: mm) assessed by echocardiography at follow-up
    Time Frame
    Baseline; 3-month, 6-month follow-up
    Title
    Change in Quality Of Life Questionnaire score between baseline and follow-up
    Description
    Reflect the effect of cardiac funtion on quality of life, and higher scores represent a worse outcome
    Time Frame
    Baseline; 3-month, 6-month follow-up
    Title
    Changes in New York Heart Association Heart Function Classification between baseline and follow-up
    Description
    The higher the classification, the more severe the heart failure symptoms(four levels: I, II, III and IV)
    Time Frame
    Baseline; 3-month, 6-month follow-up
    Title
    Changes in 6-minute Walk Distance between baseline and follow-up
    Description
    Distance that a participant walk within 6 minutes
    Time Frame
    Baseline; 3-month, 6-month follow-up
    Title
    Changes in concentration of NT-proBNP in blood between baseline and follow-up
    Description
    Blood test is performed at each time frame to determine the concentration of NT-proBNP(unit: pg/mL)
    Time Frame
    Baseline; 3-month, 6-month follow-up
    Title
    Incidence of stroke events
    Description
    Including date and number of stroke
    Time Frame
    6-month follow-up
    Title
    A combined arrhythmia endpoint of new-onset atrial fibrillation and malignant ventricular arrhythmia
    Description
    Including date and number of new-onset atrial fibrillation and malignant ventricular arrhythmia
    Time Frame
    6-month follow-up
    Title
    Success rate of LBBAP implantation Success rate of LBBAP implantation Success rate of LBBAP implantation Success rate of LBBAP implantation Success rate of LBBAP implantation
    Description
    Success rate of LBBAP in LOT-CRT group
    Time Frame
    Operative day

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    80 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Ischemic or non ischemic cardiomyopathy Optimal medical therapy for at lest 3 months NYHA class II-IV LVEF≤35% as assessed by echocardiography Sinus rhythm (may have paroxysmal atrial fibrillation) QRS duration ≥ 150ms Intraventricular block (NICD), QRS morphology is neither LBBB nor RBBB Exclusion Criteria: Valvular heart disease that requires or has undergone surgical intervention After mechanical tricuspid valve replacement Persistent or permanent atrial fibrillation or atrial flutter Second or third degree atrioventricular block Have a history of acute myocardial infarction within 3 months prior to enrollment Patient's expected survival time is less than 12 months Pregnant or planned to conceive Ventricular septal hypertrophy (ventricular septal thickness exceeds 15mm at the end of diastole) Patients with simple and persistent left superior vena cava Patients with existing pacemaker implantation
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Jiangang Zou
    Phone
    86-13605191407
    Email
    jgzou@njmu.edu.cn
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Jiangang Zou
    Organizational Affiliation
    The First Affiliated Hospital with Nanjing Medical University
    Official's Role
    Principal Investigator
    First Name & Middle Initial & Last Name & Degree
    Yangang Su
    Organizational Affiliation
    Shanghai Zhongshan Hospital
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    36137670
    Citation
    Wang Y, Zhu H, Hou X, Wang Z, Zou F, Qian Z, Wei Y, Wang X, Zhang L, Li X, Liu Z, Xue S, Qin C, Zeng J, Li H, Wu H, Ma H, Ellenbogen KA, Gold MR, Fan X, Zou J; LBBP-RESYNC Investigators. Randomized Trial of Left Bundle Branch vs Biventricular Pacing for Cardiac Resynchronization Therapy. J Am Coll Cardiol. 2022 Sep 27;80(13):1205-1216. doi: 10.1016/j.jacc.2022.07.019.
    Results Reference
    result
    PubMed Identifier
    34339851
    Citation
    Jastrzebski M, Moskal P, Huybrechts W, Curila K, Sreekumar P, Rademakers LM, Ponnusamy SS, Herweg B, Sharma PS, Bednarek A, Rajzer M, Vijayaraman P. Left bundle branch-optimized cardiac resynchronization therapy (LOT-CRT): Results from an international LBBAP collaborative study group. Heart Rhythm. 2022 Jan;19(1):13-21. doi: 10.1016/j.hrthm.2021.07.057. Epub 2021 Jul 30.
    Results Reference
    result

    Learn more about this trial

    A Randomized Controlled Trial of LOT-CRT Versus conventionaL BiVP in Heart Failure Patients With NICD

    We'll reach out to this number within 24 hrs